Phase II trial of pegylated interferon-α2b in patients with advanced renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 6, Issue 1, 2008, Pages 25-30

  Feldman, Darren R ^a,b   Kondagunta, G Varuni ^a,b   Schwartz, Lawrence ^a,b   Patil, Sujata ^a,b   Ishill, Nicole ^a,b   DeLuca, John ^a,b   Russo, Paul ^a,b   Motzer, Robert J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biologic response modifier; Hyperkalemia; Hyponatremia; Lung metastasis; Transaminitis

Indexed keywords

ALPHA2B INTERFERON;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FEMALE; HUMAN; HYPERKALEMIA; HYPONATREMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTOPENIA; MALE; MEDICAL ASSESSMENT; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 43249093067     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.n.004     Document Type: Article

References (22)

1. O Rixe RM Bukowski MD Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
2. RJ Motzer BA Murphy J Bacik Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J Clin Oncol 18 2000 2972 2980
3. Medical Research Council Renal Cancer Collaborators Interferonalpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial Lancet 353 1999 14 17
4. S Pyrhönen E Salminen M Ruutu Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer J Clin Oncol 17 1999 2859 2867
5. MP Wirth Immunotherapy for metastatic renal cell carcinoma Urol Clin North Am 20 1993 283 295
6. B Escudier N Lassau E Angevin Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma Clin Cancer Res 13 2007 1801 1809
7. JA Gollob WK Rathmell TM Richmond Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 2007 3288 3295
8. CW Ryan BH Goldman PN Lara Jr Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group J Clin Oncol 25 2007 3296 3301
9. R Bukowski MS Ernstoff ME Gore Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study J Clin Oncol 20 2002 3841 3849
10. KL Lindsay C Trepo T Heintges A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
11. M Talpaz Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition Semin Hematol 38 2001 22 27
12. JE Korkola GV Kondagunta VE Reuter Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profiling J Urol 177 2007 1264 1268 discussion 1268.
13. AB Miller B Hoogstraten M Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
14. DF Cella DS Tulsky G Gray The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
15. DL Fairclough DF Cella Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions Qual Life Res 5 1996 321 329
16. RJ Motzer J Bacik BA Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
17. RJ Motzer MD Michaelson BG Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24
18. RJ Motzer BI Rini RM Bukowski Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524
19. A Bex H Mallo M Kerst A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor Cancer Immunol Immunother 54 2005 713 719
20. G Hudes M Carducci P Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
21. RJ Motzer TE Hutson P Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
22. B Escudier A Pluzanska P Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111